Avita Medical (RCEL) Projected to Announce Earnings on Thursday

Avita Medical (NASDAQ:RCEL) is projected to post its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.2928) per share and revenue of $20.25 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Avita Medical (NASDAQ:RCEL) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.35). The business had revenue of $19.25 million during the quarter, compared to analyst estimates of $18.30 million. On average, analysts expect Avita Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Avita Medical Price Performance

Avita Medical stock opened at $4.62 on Tuesday. The firm has a 50-day moving average of $4.39 and a 200-day moving average of $4.37. Avita Medical has a one year low of $3.22 and a one year high of $7.12. The company has a market cap of $142.20 million, a price-to-earnings ratio of -2.94 and a beta of 1.86.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Wall Street Zen upgraded Avita Medical from a “sell” rating to a “hold” rating in a report on Sunday. Weiss Ratings reissued a “sell (e+)” rating on shares of Avita Medical in a research report on Wednesday, June 24th. TD Cowen restated a “buy” rating on shares of Avita Medical in a research note on Tuesday, June 30th. Lake Street Capital raised Avita Medical from a “hold” rating to a “buy” rating and boosted their price target for the stock from $3.50 to $6.00 in a research report on Friday, May 15th. Finally, D. Boral Capital reiterated a “buy” rating and set a $10.00 price objective on shares of Avita Medical in a research note on Wednesday, April 8th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $7.25.

Insider Activity at Avita Medical

In related news, Director Joseph Fralin Woody acquired 10,000 shares of the firm’s stock in a transaction on Tuesday, June 9th. The shares were purchased at an average cost of $4.19 per share, for a total transaction of $41,900.00. Following the completion of the acquisition, the director directly owned 102,761 shares in the company, valued at approximately $430,568.59. This trade represents a 10.78% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have acquired 37,200 shares of company stock valued at $155,080 in the last 90 days. 2.24% of the stock is owned by insiders.

Institutional Trading of Avita Medical

Hedge funds and other institutional investors have recently modified their holdings of the stock. Deutsche Bank AG raised its holdings in Avita Medical by 1,351.5% in the 4th quarter. Deutsche Bank AG now owns 7,896 shares of the company’s stock valued at $27,000 after acquiring an additional 7,352 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of Avita Medical by 122.2% during the fourth quarter. Russell Investments Group Ltd. now owns 8,047 shares of the company’s stock worth $28,000 after acquiring an additional 4,425 shares during the period. Aristides Capital LLC acquired a new position in shares of Avita Medical in the fourth quarter valued at approximately $48,000. The Manufacturers Life Insurance Company acquired a new position in shares of Avita Medical in the second quarter valued at approximately $58,000. Finally, Wells Fargo & Company MN increased its stake in shares of Avita Medical by 98.5% during the fourth quarter. Wells Fargo & Company MN now owns 18,832 shares of the company’s stock worth $65,000 after purchasing an additional 9,345 shares during the period. Institutional investors own 27.66% of the company’s stock.

About Avita Medical

Avita Medical, Inc (NASDAQ: RCEL) is a regenerative medicine company focused on the development and commercialization of cell‐based therapies for acute and chronic wounds. Its flagship technology, the ReCell® Autologous Cell Harvesting Device, enables clinicians to create a suspension of a patient’s own skin cells at the point of care. The system is designed to accelerate wound healing, minimize donor‐site requirements and reduce scarring for patients suffering from burns, traumatic wounds and a variety of surgical and reconstructive procedures.

Founded in 2009 and headquartered in Carlsbad, California, Avita Medical has secured regulatory clearances in key markets, including CE mark approval in the European Union and 510(k) clearance from the U.S.